Page 9 - Quick Inventory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The addition of fluoxetine to CBT did not further reduce depressive symptoms in young people with moderate-to-severe depression.

Investegate announcements from COMPASS Pathways, COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse events demonstrate

(0) Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS's COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a sel...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. New England Journal of Medicine publishes exploratory study showing signals of positive ... COMPASS Pathfinder Ltd.April 15, 2021 GMT London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the  New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin com...